U.S. markets open in 4 hours 53 minutes
  • S&P Futures

    4,216.50
    +6.50 (+0.15%)
     
  • Dow Futures

    33,326.00
    +66.00 (+0.20%)
     
  • Nasdaq Futures

    13,418.25
    +26.25 (+0.20%)
     
  • Russell 2000 Futures

    1,974.40
    +4.90 (+0.25%)
     
  • Crude Oil

    91.98
    +0.05 (+0.05%)
     
  • Gold

    1,802.60
    -11.10 (-0.61%)
     
  • Silver

    20.42
    -0.32 (-1.55%)
     
  • EUR/USD

    1.0331
    +0.0029 (+0.28%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    20.05
    -1.72 (-7.90%)
     
  • GBP/USD

    1.2227
    +0.0009 (+0.07%)
     
  • USD/JPY

    132.5660
    -0.3070 (-0.23%)
     
  • BTC-USD

    24,483.91
    +1,446.90 (+6.28%)
     
  • CMC Crypto 200

    575.78
    +44.56 (+8.39%)
     
  • FTSE 100

    7,502.91
    -4.20 (-0.06%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Soliton Stock Rallies After $22.60/Share Buyout From AbbVie

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AbbVie Inc (NYSE: ABBV) is making an opportunistic play to boost the aesthetics business by adding a long-delayed body sculpting product into the fold.

  • AbbVie’s Allergan Aesthetics unit will pay 0 million in cash to scoop up Soliton Inc (NASDAQ: SOLY) and Resonic, its sound-wave device that improves the appearance of cellulite.

  • Under the terms of the transaction, Allergan Aesthetics will pay $22.60 per share in cash for each outstanding share of Soliton.

  • The body sculpting offering will help add some heft to the Allergan Aesthetics brand, which includes cosmetic Botox as its most visible product.

  • AbbVie propped up the aesthetics business as part of its $63 billion buyout of Allergan last year, keeping Botox’s therapeutic indications under the AbbVie brand.

  • Allergan Aesthetics already has a product in CoolSculpting Elite. Still, the Soliton pickup adds a non-invasive option in Resonic, which also holds approval in tattoo removal alongside lasers and improves the appearance of fibrotic scars.

  • Cosmetic Botox cleared $447 million in the first quarter, a 44.7% Y/Y increase. The unit, on the whole, made $1.14 billion in sales on the quarter. Meanwhile, the overall AbbVie business cleared more than $13 billion in sales on the quarter, led once again by Humira at $3.9 billion.

  • Price Action: SOLY shares are up 23.7% at $22.27, while ABBV shares are up 0.31% at $116.12 during the market trading session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.